Should the new owner of a troubled company change the name or tough it out in hopes that memories are short and images can be remade This is the choice facing Sun Pharmaceutical as it ponders the value and perception of the Ranbaxy Laboratories name in the US where the Indian generic drug maker has become something of a poster child for qualitycontrol issues Last year Ranbaxy reached a  million settlement with the US government to resolve   among other things The deal however did not end its troubles The FDA has banned imports of Ranbaxy products from four plants in India  causing the US Department of Veterans Affairs to end contracts for two drugs  and the US Attorney in New Jersey recently issued subpoenas for documents concerning manufacturing issues at one of those facilities After years of aggravation Daiichi Sankyo earlier this month   in Ranbaxy to Sun Pharma for  billion More on this after the jump